AIM:BVXP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. More Details


Snowflake Analysis

Flawless balance sheet with outstanding track record and pays a dividend.

Share Price & News

How has Bioventix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BVXP is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: BVXP's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-2.4%

BVXP

-1.3%

GB Biotechs

-0.4%

GB Market


1 Year Return

13.5%

BVXP

25.5%

GB Biotechs

-10.1%

GB Market

Return vs Industry: BVXP underperformed the UK Biotechs industry which returned 25.3% over the past year.

Return vs Market: BVXP exceeded the UK Market which returned -11% over the past year.


Shareholder returns

BVXPIndustryMarket
7 Day-2.4%-1.3%-0.4%
30 Day-2.8%-5.5%13.4%
90 Day-4.8%2.8%6.4%
1 Year17.6%13.5%26.0%25.5%-6.5%-10.1%
3 Year73.1%54.6%5.0%3.7%1.5%-10.9%
5 Year287.4%216.2%35.8%33.2%27.4%-1.6%

Long-Term Price Volatility Vs. Market

How volatile is Bioventix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bioventix undervalued compared to its fair value and its price relative to the market?

28.69x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BVXP (£40) is trading above our estimate of fair value (£27.18)

Significantly Below Fair Value: BVXP is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BVXP is good value based on its PE Ratio (28.7x) compared to the XE Biotechs industry average (41.7x).

PE vs Market: BVXP is poor value based on its PE Ratio (28.7x) compared to the UK market (20.9x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BVXP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BVXP is overvalued based on its PB Ratio (16.6x) compared to the GB Biotechs industry average (5.1x).


Next Steps

Future Growth

How is Bioventix forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioventix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Bioventix performed over the past 5 years?

17.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BVXP has high quality earnings.

Growing Profit Margin: BVXP's current net profit margins (69.8%) are higher than last year (63.1%).


Past Earnings Growth Analysis

Earnings Trend: BVXP's earnings have grown by 17.7% per year over the past 5 years.

Accelerating Growth: BVXP's earnings growth over the past year (22.8%) exceeds its 5-year average (17.7% per year).

Earnings vs Industry: BVXP earnings growth over the past year (22.8%) exceeded the Biotechs industry 11.2%.


Return on Equity

High ROE: BVXP's Return on Equity (57.5%) is considered outstanding.


Next Steps

Financial Health

How is Bioventix's financial position?


Financial Position Analysis

Short Term Liabilities: BVXP's short term assets (£12.0M) exceed its short term liabilities (£728.6K).

Long Term Liabilities: BVXP's short term assets (£12.0M) exceed its long term liabilities (£50.2K).


Debt to Equity History and Analysis

Debt Level: BVXP is debt free.

Reducing Debt: BVXP has not had any debt for past 5 years.

Debt Coverage: BVXP has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BVXP has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Bioventix current dividend yield, its reliability and sustainability?

3.52%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: BVXP's dividend (3.53%) is higher than the bottom 25% of dividend payers in the UK market (1.72%).

High Dividend: BVXP's dividend (3.53%) is low compared to the top 25% of dividend payers in the UK market (5.01%).


Stability and Growth of Payments

Stable Dividend: BVXP's dividends per share have been stable in the past 10 years.

Growing Dividend: BVXP's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (63.1%), BVXP's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.8yrs

Average board tenure


CEO

Peter Harrison (62 yo)

no data

Tenure

UK£284,756

Compensation

Mr. Peter John Harrison, MA, serves as the Chief Executive Officer of Bioventix PLC. Mr. Harrison has worked in the field of antibody technology since 1986 and has extensive experience of the development a...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD379.54K) is below average for companies of similar size in the UK market ($USD620.37K).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Peter Harrison
CEO & Directorno dataUK£284.76k8%
£ 16.6m
Bruce Edward Hiscock
CFO & Director0.33yrno datano data
Ian Nicholson
Independent Non-Executive Chairman16yrsUK£48.65k0.30%
£ 616.1k
Nicholas McCooke
Independent Non-Executive Director6.83yrsUK£39.14kno data

6.8yrs

Average Tenure

61.5yo

Average Age

Experienced Board: BVXP's board of directors are considered experienced (6.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bioventix PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bioventix PLC
  • Ticker: BVXP
  • Exchange: AIM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£207.071m
  • Shares outstanding: 5.21m
  • Website: https://www.bioventix.com

Number of Employees


Location

  • Bioventix PLC
  • 27-28 Eastcastle Street
  • London
  • Greater London
  • W1W 8DH
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BVXPAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPApr 2010
51BDB (Deutsche Boerse AG)YesOrdinary SharesDEEURApr 2010

Biography

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/27 19:53
End of Day Share Price2020/11/27 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.